The therapeutic efficacy of CD4+Lrig1+ T cells was confirmed in chronic IBD and lupus genetic-animal model through the adoptive transfer, which is comparable to that of CD4+Foxp3+ T cells in the IBD model and CD4+CD25+ T cells or methylprednisolone in the lupus-prone model. This evidence concerns the gene LRIG1 and inflammatory bowel disease.